AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
AbbVie (ABBV) shares rise on earnings beat - prepared for loss of Humira exclusivity
February 9, 2023 10:00 AM ESTAbbVie (NYSE: ABBV) shares are up more than 3% in early Thursday trading after the company topped earnings estimates for the fourth quarter.
Earnings came in at $3.60 per share, $0.07 better than the analyst estimate of $3.53. However, the biotech firm missed the analyst consensus revenue forecast of $15.33 billion, coming in at $15.12 billion.
The company's results included an unfavorable impact of $0.13 per share related to the fourth-quarter 2022 acquired IPR&D and milestones expense.
The... More
AbbVie (ABBV) Tops Q4 EPS by 7c, Offers Guidance
February 9, 2023 7:46 AM ESTAbbVie (NYSE: ABBV) reported Q4 EPS of $3.60, $0.07 better than the analyst estimate of $3.53. Revenue for the quarter came in at $15.12 billion versus the consensus estimate of $15.33 billion.
These Results Include an Unfavorable Impact of $0.13 Per Share Related to Fourth-Quarter 2022 Acquired IPR&D and... More